Site-specific drug release of monomethyl fumarate to treat oxidative stress disorders.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39496929.
- Also identified by DOI 10.1038/s41587-024-02460-4 and PMC identifier 12049564.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Treatment of diseases of oxidative stress through activation of the antioxidant nuclear factor E2-related factor 2 (NRF2) is limited by systemic side effects. We chemically functionalize the NRF2 activator monomethyl fumarate to require Baeyer-Villiger oxidation for release of the active drug at sites of oxidative stress. This prodrug reverses chronic pain in mice with reduced side effects and could be applied to other disorders of oxidative stress.
Medical subject headings
- Oxidative Stress
- Fumarates
- Prodrugs
- Chronic Pain